Physician profile
Yaffa Fishman
NPI 1013027226
$1,965.37
in general payments reported to CMS, 2019-2025
12 companies · $125 in 2025
The $125 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,361 · 2020: $169 · 2022: $250 · 2023: $60.68 · 2025: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $186.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $185.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $584.00 | 2019-2025 | Lokelma |
| Genzyme Corporation | $343.37 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $249.88 | 2022 | |
| Optinose US, INC. | $212.10 | 2019-2020 | |
| Glaxosmithkline, LLC. | $185.38 | 2019 | |
| Pfizer INC. | $179.11 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $113.63 | 2019 | |
| Shire North American Group INC | $22.31 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.83 | 2020 | |
| Novartis Pharmaceuticals Corporation | $18.95 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.00 | 2019 | |
| Alk-Abello, INC | $17.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yaffa Fishman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.